I'm with Seb on this one. There were some good things in the AGM address, but the traditional EBITBA skew of 65% 1H vs 35% 2H is very troubling. The 1H17 EBITDA sounds like it will be ~$25m. Requires a massive turnaround in the 2H (ie ~$35-40m) to achieve FY17 EBITDA of $60-65m. History suggests the 2H faith stories rarely deliver ...
- Forums
- ASX - By Stock
- Ann: AGM Chair and Managing Director & CEO Addresses
I'm with Seb on this one. There were some good things in the AGM...
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BBG (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham, CEO
James Graham
CEO
Previous Video
Next Video
SPONSORED BY The Market Online